Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 1, 2007, Pages 140-141

  Yoles, I ^a   Lilling, G ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DT56A; ESTRADIOL; FEMARELLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER CELL CULTURE; CANCER RISK; CELL GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; LETTER; PRIORITY JOURNAL;

EID: 33845477900     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.02.010     Document Type: Letter

References (6)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002, July 7) 321-333
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
3. Somjen D., and Yoles I. DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J Steroid Biochem Mol Biol 86 1 (2003) 93-98
4. Yoles I., Yogev Y., Frenkel Y., Nahum R., and Hirsch M. Kaplan B Tofupill/Femarelle (DT56a)-a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 10 6 (2003) 522-525
5. Oropeza M.V., Orozco S., Ponce H., and Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. Reprod Toxicol 20 2 (2005 July-August) 261-266
6. Simstein R., Burow M., Parker A., Weldon C., and Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228 9 (2003) 995-1003